This paper links the main issues of the project "Contested World Order" (WZB, GIGA, HSFK) to the policy field of global health: the authority of the institutional setting, and the preferences and strategies of rising powers and non-state actors (NStAs) - the assumed protagonists of recent power shifts. The first part discusses the loss of WHO authority since the rise of Global Health Governance, and WHO's fight to reassert its position. The core of the paper deals with the conflict on intellectual property rights (IPRs) and access to medicines as a central issue in global health. Between 1995 and 2005, civil society organizations (CSOs) and some emerging powers fought successfully for improving access conditions under the TRIPS agreement (D...
This article discusses the human right to health in the context of patent protection and access to m...
Few issues are as controversial as the impact of intellectual property on health in developing count...
Summary: 1. Pharmaceutical patents, the access to essential medicines and the question of innovation...
Any system for the protection of intellectual property rights (IPRs) has three main kinds of distrib...
In the past several years, the impact of intellectual property rights (IPRs) on access to medicines ...
Access to medicines is a human right, enshrined in legally binding international human rights treati...
Civil society organizations and other non-governmental organizations (NGOs) act as policy watchdogs ...
The coming into force of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRI...
In this introduction we briefly review the literature on intellectual property rights and access to ...
Human rights have been diffused by waves of globalisation that also swell the economic forces of tra...
Human rights have been diffused by waves of globalisation that also swell the economic forces of tra...
The Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) firmly enshrined a le...
Over the past fifteen years, the United States and other developed countries have employed trade agr...
This issue of Globalization and Health presents a paper by Kerry and Lee that considers the TRIPS a...
Developing countries have limited control over the distributional and substantive dimensions of inte...
This article discusses the human right to health in the context of patent protection and access to m...
Few issues are as controversial as the impact of intellectual property on health in developing count...
Summary: 1. Pharmaceutical patents, the access to essential medicines and the question of innovation...
Any system for the protection of intellectual property rights (IPRs) has three main kinds of distrib...
In the past several years, the impact of intellectual property rights (IPRs) on access to medicines ...
Access to medicines is a human right, enshrined in legally binding international human rights treati...
Civil society organizations and other non-governmental organizations (NGOs) act as policy watchdogs ...
The coming into force of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRI...
In this introduction we briefly review the literature on intellectual property rights and access to ...
Human rights have been diffused by waves of globalisation that also swell the economic forces of tra...
Human rights have been diffused by waves of globalisation that also swell the economic forces of tra...
The Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) firmly enshrined a le...
Over the past fifteen years, the United States and other developed countries have employed trade agr...
This issue of Globalization and Health presents a paper by Kerry and Lee that considers the TRIPS a...
Developing countries have limited control over the distributional and substantive dimensions of inte...
This article discusses the human right to health in the context of patent protection and access to m...
Few issues are as controversial as the impact of intellectual property on health in developing count...
Summary: 1. Pharmaceutical patents, the access to essential medicines and the question of innovation...